The study will examine the efficacy of four drugs—an antiviral and three monoclonal antibodies—that are already being used to treat patients in Democratic Republic of Congo.

Some patients could suppress the virus without antiretroviral therapy for months after the drug infusions.

The number of cases in Democratic Republic of Congo’s latest outbreak of the virus has now surpassed 100.  

The monoclonal antibody, known as mAb114, is likely to be used in the current Ebola outbreak in DRC.

Synthetic and natural alternatives to traditional antibodies offer more control, specificity, and reproducibility. 

Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen Pseudomonas aeruginosa.

A new method stimulates B cells to make human antigen-specific antibodies, obviating the need for vaccinating blood donors or hunting for rare B cells.

Researches develop a human monoclonal antibody against two filoviruses, Marburg and Ravn, which, like Ebola, can cause hemorrhagic fever.

See what cytokine activity and cellular starvation have to do with cancer metastasis.